← board
ONC
distress 0/10 · well-funded / low risk$320.32+0%today-15% from 52w high
Revenue
$1513M
Liquidity
$4860M
Runway
—
Shares 1y
+1%
Price & events
-5.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+0.9%
1W
+16.0%
1M
+6.8%
3M
-5.6%
6M
+8.6%
1Y
+103.3%
2Y
+1.1%
5Y
+22.7%
All
Overview
- Market Cap
- $462.95B
- Enterprise Value
- $459.12B
- Volume
- 36.72K
- 52 Week Range
- $250 – $377
- Total Shares
- 1.45B
- Float Shares
- 78.22M
- Short %
- 1.12%
- % Held by Insiders
- 17.29%
- % Held by Institutions
- 32.98%
- RVOL
- 0.11x
- Beta
- 0.49
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $415 (+30% upside) · 27 analysts
- 2026-07-14BarclaysOverweight
- 2026-07-13JefferiesHold → Buy
- 2026-07-07RBC CapitalOutperform
- 2026-07-07Truist SecuritiesBuy
- 2026-07-01CitizensMarket Outperform
- 2026-06-02RBC CapitalOutperform
Competitors
- none identified
Recent news
- 2026-07-23BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines - Business Wire
- 2026-07-21ONC Stock Price and Chart — NASDAQ:ONC - TradingView
- 2026-07-21ONC Stock Price and Chart — NASDAQ:ONC - TradingView
- 2026-07-19BeOne Medicines Ltd. Announces Q2 2026 Financial Results Release Date and Audit Committee Review - Minichart
- 2026-07-19BeOne Medicines (ONC) Slips 1.7% as Shares Test Near-Term Support Levels - Value Area High - dars.gov.et
- 2026-07-17BeOne Medicines to announce Q2FY26 results on August 5 - scanx.trade
- 2026-07-14Form 144 BEONE MEDICINES LTD For: 14 July By Investing.com - Investing.com India
- 2026-07-14ONC stock (NASDAQ: ONC) holders file to sell 513,574 ADS - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.